Publications

Scientific Literature & Publications

 

Title

Source

Description

FASEB Journal vol. 31 no. 1 Supplement 786.18, Experimental Biology Congress, April 22-26, 2017 Chicago, FL
To evaluate blood collection devices to identify ones best suited to obtain DMS for measurement of Nbs.

21st Internationl Congress of Nutrition, October 15-20, 2017, Buenos Aires, Argentina
Dry matrix spots (DMS) are dried spots of bodily fluids such as blood, serum, and urine. These have been used for many years for specimen collection in remote areas of the world. The goal of this study was to compare different methods of blood collection devices (BCDs) and identify those that could isolate purified plasma from whole blood for downstream nutritional biomarker (NB) testing.

HEP DART 2015, December 4-8, 2015, Wailea, Hawaii.
Describes the use of ViveST technology to produce dried, thermostable serological controls which were rehydrated and analyzed in assay controls and calibrators.

HEP DART 2015, December 4-8, 2015, Wailea, Hawaii.
Summarizes the functionality and performance of a prototype plasma separation card that allows plasma to be collected via a finger prick.

Kidney Week 2015, November 3-8, 2015, San Diego, California.
Detection of CXCL9/MIG and CXCL10/IP-10 in urine spectrophotometrically with ViveST, a novel collection device.

AMP 2015, November 5-8, 2015, Austin, Texas.
Tested analytes such as viruses and bacteria at ambient temperature and elevated temperature in both liquid format and dry storage.

AMP 2015, November 5-8, 2015, Austin, Texas.
Two sets of HCV controls and one set of HIV controls were analyzed in their native frozen state and compared to ViveST dried, thermostable state.

AMP 2015, November 5-8, 2015, Austin, Texas.
The functionality and performance of a novel prototype plasma separation card that separate cellular components via an asymmetric membrane allowing plasma to be collected and stored.

Am. J. Trop. Med. Hyg., 93(1), 2015, pp. 46-53, doi: 10.4269/ajtmh.15-0110, Copyright© 2015 by the American Society of Tropical Medicine and Hygiene.
This study used dengue virus as a model RNA virus for testing three clinical specimen stabilization products for their ability to preserve nucleic acid and antibody in a dried blood format.

31st Annual Clinical Virology Symposium, April 26-29, 2015, Daytona Beach, FL.
This study evaluates the use of ViveST for storage and shipment of molecular diagnostics controls.

2015 International HIV Drug Resistance Workshop, February 21-22, 2015, Seattle, Washington.
Evaluated HIV drug resistance in drug-naïve patients 10 years after being treated with combination anti-retroviral therapy (cART).

2014 HIV DART, December 9-12, 2014, Miami, Florida.
Proof of concept study describing the functionality and performance of a new plasma separation card.

2014 Association for Molecular Pathology, November 12-15, 2014, National Harbor, MD.
This study evaluated the stability of HIV-1 plasma samples shipped and stored on ViveST®.

2014 American Society of Tropical Medicine and Hygiene, November 2-5, 2014, New Orleans, LA.
Tested down-selected products in the field by using them to ship clinical dengue-positive whole blood samples from Iquitos to Lima, Peru for analysis.

2014 Clinical Virology Symposium, April 27-30, 2014, Daytona Beach, FL.
This study evaluates the storage of low titer HCV plasma using ViveST™ in combination with Abbott RealTime HCV assay.

HEP DART 2013, held December 8-12, 2013 in Hawaii.
This study demonstrates the utility of ViveST™ for transportation and storage of HBV infectious plasma.

American Society of Tropical Medicine and Hygiene, November 13-17, 2013, Washington D.C.
Evaluation of four commercially available RNA-stabilization products using whole blood.

Association of Molecular Pathology, November 14-16, 2013, Phoenix, AZ
Evaluated the performance of ViveST™ as a storage and transport device for downstream molecular based viral load assays.

ID Week, Annual Meeting of the Infectious Disease Society of America, October 2-6, 2013, San Francisco, California
Evaluated the performance of ViveST as a storage and transport device for use with viral load and drug resistance.

International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, June 4-8, 2013, Toronto, Canada
Evaluated the performance of ViveST as a storage and transport device for use with viral load and drug resistance.

29th Clinical Virology Symposium, April 28-May 1, 2013, Daytona Beach, FL
Evaluated the stability of infectious plasma samples stored on ViveST™ and analyzed with the Abbott RealTime HCV and HIV-1 viral load assays.

29th Clinical Virology Symposium, April 28-May 1, 2013, Daytona Beach, FL
Evaluated the performance of COBAS® TaqMan® HCV Test, v2.0 when using HCV infected samples stored and processed on ViveST™.

HIV DART 2012 (Drug Development for Antiretroviral Therapies) held in San Diego, CA, December 4-7, 2012
Compares the cost of shipping frozen plasma to the cost of shipping plasma at ambient temperature using ViveST™

Association for Molecular Pathology (AMP) 2012 Annual Meeting held in Long Beach, CA, October 25 – 27, 2012
Assessment of the performance of ViveST, a novel dried ambient transportation matrix, to frozen plasma for use with commercially available HCV and HIV-1 viral load and genotypic assays.

Barr KL, Messenger AM, Anderson BD, Friary JA , Heil GL, Reese K, and Gray GC. Recovery of Live Virus after Storage at Ambient Temperature Using ViveST™. J Clin Virology, in press October 2012.
Examines the ability of ViveST™ to preserve live virus following storage at ambient temperature.

2012 International Conference on Emerging Infectious Diseases (ICEID) held in Atlanta, GA, USA, March 11-14, 2012.
Studies difficulty of shipping frozen samples of various virus in developing nations where there are the lack of ultralow temperature freezers.

Journal of Clinical Virology, December 2010, p. 245-248.
Assesses the reproducibility of ViveST and compares HIV viral load results from ViveST to those from frozen plasma.

Journal of Clinical Microbiology, January 2012, p. 145-147.
Assesses the reproducibility of ViveST and compares HBV viral load results from ViveST to those from frozen plasma.

Journal of Clinical Microbiology, May 2009, p. 1491-1496
A comparison of ViveST (previously SampleTanker) against frozen plasma with multiple analytes for both shipping and storage.

The International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies, June 5-9, 2012, Stiges, Spain
Compares the performance of ViveST, a dried transport matrix, to plasma for viral load determination with the Abbott RealTime HCV viral load assay.

The 28th Annual Clinical Virology Symposium, April 20-25, 2012, Daytona Beach, Florida
Compares the performance of ViveST, a dried transport matrix, to frozen plasma for use with commercially available HCV and HIV-1 viral load and genotypic assays.

Influenza and Other Respiratory Viruses, Nov 2011, p. 413-417
A comparison of ViveST against frozen plasma storage of specimens tested for detection of influenza RNA.

26th Clinical Virology Symposium; April 25-28, 2010; Daytona Beach, FL, USA
An evaluation of ViveST for plasma samples containing three different hepatitis virus; HBV, HCV and HDV.

IAS 2009; July 19-22, 2009; Cape Town, South Africa
Compares fresh-frozen plasma samples to ViveST for HIV genotyping. The samples are shipped internationally from Israel and the UK, and nationally from California to Georgia.

4th International Workshop on HIV Transmission-Principles of Intervention; July 17-18, 2009; Cape Town, South Africa
Utilizes ViveST for transport of HIV genotypes utilizing low-tech methods.

4th International Workshop on HIV Transmission-Principles of Intervention; July 17-18, 2009; Cape Town, South Africa
Examines HIV diversity and drug resistance in western Kenya using frozen plasma and ViveST.

7th European HIV Drug Resistance Workshop, March 25-27, 2009; Stockholm, Sweden
Compares plasma, dried plasma (ViveST), and dried blood spots genotypic analysis utilizing a prototype TRUGENE CLIP module for the TRUGENE HIV-1 integrase assay.

20th International Congress of Clinical Chemistry and Laboratory Medicine, September 28th – October 2, 2008; Fortaleza, Brazil
Reviews the performance of ViveST using the new Siemens integrase sequencing assay.

24th Clinical Virology Symposium; April 25-29, 2008; Daytona Beach, FL, USA
Compares the precision and stability of ViveST vs. fresh-frozen plasma. Five replicates of each sample were stored at different temperatures, measured at 5 points from day 2 through day 56. Two commercial HIV-1 viral load assays used: Roche Amplicor 1.5 and Abbott M2000.

11th European AIDS Conference; October 24-27, 2007; Madrid, Spain
Compares ViveST to fresh frozen plasma for viral trophism, phenotypes, and genotypes.

XIV International HIV Drug Resistance Workshop; June 7-11, 2005; Quebec City, Canada
Compares fresh-frozen plasma to ViveST plasma; whole blood to ViveST-WB; and PBMC extractions.

21st Clinical Virology Symposium; May 8-11, 2005; Clearwater Beach, FL, USA
Demonstrates the viability of ViveST for HBV utilizing two different extraction methods, then processed on LiPA strips directed at three different areas on the HBV genome. All proved successful.

12th Conference on
Retroviruses and
Opportunistic
Infections; February
22-25, 2005; Boston,
MA, USA
ViveST specimens were prepared and compared to FFP. The comparisons were TRUGENE HIV-1 Genotyping, HIV-1 GeneTanker complete and analyzed with MuTanker software. Samples were shipped from Israel.

XIII International HIV Drug Resistance Workshop; June 8-12, 2004; Tenerife Sur-Costa Adeje, Canary Islands, Spain
Demonstrates the viability of ViveST with multiple commercial FDA-approved HIV-1 assays. It also demonstrated excellent results with genotyping both in HIV with TREGENE and hepatitis C.

The Journal of Infectious Diseases, September 2006
Highlights some of the history, accomplishments, and impact of Tom Merigan’s laboratory on the use of HIV-1 load as a marker, as well as on updating technologies for determining HIV-1 load, their performance, interpretation of the results, and their use in clinical practice.